News

Antibiotic resistance changes treatable infections into significant health threats. Along with the clinical challenges comes an extra financial load, as antibiotic resistance typically adds around $1,400 to the hospital bill for treating bacterial infections, according to the CDC in the US. This steep rise indicates a concerning trend where healthcare costs climb hand-in-hand with the complexity of treating resistant strains.

Resistell, an EPFL spin-off developing rapid phenotypic antibiotic susceptibility testing (AST) solutions, announces the peer-reviewed article in the Nature Communications journal. The publication marks the completion of the company’s technology validation stage and showcases the potential of the Resistell nanomotion technology platform as a diagnostic in the fight against antimicrobial resistance (AMR).

With a remarkable 25-year journey at the forefront of healthcare innovation, Trevor brings a wealth of experience from his leadership roles across research, clinical, and corporate spheres globally. His track record of innovation, coupled with a profound understanding of the healthcare industry’s challenges and opportunities, makes him an invaluable addition to our team. Welcome aboard, Trevor!

Cellectric, Resistell and Lausanne University Hospital will collaborate on a joint Eurostars project to build Phenotech-CF, a workflow that will reshape how antimicrobials are delivered to patients suffering from cystic fibrosis.